New evidence is showing that COVID-19 may increase a person’s risk of diabetes, but it could be years until we know for sure. In the meantime, Dexcom (Nasdaq:DXCM) is getting ready, VP of Global Clinical Initiatives Tomas Walker said. Walker recently spoke with Medical Design & Outsourcing to discuss the San Diego-based diabetes device developer’s proactive approach […]
Diabetes
GlucoTrack provides positive update on next-gen glucose monitor
GlucoTrack (Nasdaq:GCTK) announced today that its second-generation glucose monitor device has shown promising results in analyses. Rutherford, New Jersey-based GlucoTrack — formerly known as Integrity Applications (Nasdaq:IGAP) — earlier this year completed lab testing of the non-invasive GlucoTrack 2.0 clinical prototype system and has observed better-than-expected accuracy and performance with the technology. According to a […]
Tandem Diabetes Care adds two new members to its board
Tandem Diabetes Care (Nasdaq:TNDM) announced today that it appointed two new independent members to its board of directors. Myoung Cha and Joao Malagueira have been named to the San Diego-based automated insulin delivery technology developer’s board, effective yesterday. “We welcome Joao and Myoung to our board of directors at this exciting stage in Tandem’s evolution,” […]
Senseonics wins CE mark approval for 180-day Eversense E3 CGM
Senseonics (NYSE:SENS) announced today that it received CE mark for the next-generation Eversense E3 CGM system. Germantown, Maryland-based Senseonics offered a previous-generation continuous glucose monitor (CGM) with a 90-day wear time. Its next-generation Eversense E3 can be used for up to six months (180 days). Europe already had a 180-day Senseonics CGM system available (Eversense […]
GI Dynamics EndoBarrier meets endpoints in diabetes, obesity study
GI Dynamics today announced the results of a study of its EndoBarrier system that met efficacy and safety endpoints. Boston-based GI Dynamics designed its EndoBarrier endoscopically delivered device therapy as a non-surgical, alternative treatment for type 2 diabetes and obesity for patients who do not have adequate control of their conditions through their current medication and […]
Dexcom quadruples number of shares
Dexcom (Nasdaq:DXCM) recently filed a restated certificate of incorporation to effect a four-for-one forward stock split. Shares of DXCM were down 0.9% at $293.85 per share at market close on Friday, June 10. Following the stock split, shares moved down 75.33% to $72.50 before the market opened this morning. At market open, shares were down […]
Data supports Beta Bionics’ iLet bionic pancreas
Beta Bionics announced today that a trial of its iLet bionic pancreas met key endpoints, including reduced HbA1c. Dr. Roy W. Beck and clinical investigators presented the results of the multi-center, randomized Insulin-Only Bionic Pancreas Pivotal Trial (IO BPPT) at the American Diabetes Association (ADA) 82nd Scientific Sessions in New Orleans. Read: The biggest stories […]
DarioHealth closes $50M loan facility with OrbiMed
DarioHealth (Nasdaq:DRIO) announced today that it closed a senior secured term loan facility worth up to $50 million. OrbiMed, a leading healthcare investor, will provide non-dilutive capital to fund the continued development of New York-based DarioHealth’s digital health platform for managing chronic diseases, including diabetes. According to a news release, the five-year, $50 million facility includes […]
The biggest stories from the American Diabetes Association (ADA) 2022 Scientific Sessions
For the 82nd time, the American Diabetes Association (ADA) Scientific Sessions convened to highlight all the innovations within the diabetes technology space. Major players like Dexcom, Medtronic, Abbott, Insulet and more continue to plug along, while companies like Bigfoot Biomedical, One Drop and others shared data backing the technology that they bring to the table. […]
Digital therapeutics developer Better Therapeutics names new CEO
Better Therapeutics (Nasdaq:BTTX) announced today that it appointed Frank Karbe as its new president and CEO. San Francisco-based Better Therapeutics develops prescription digital therapeutics (PDTs) based on nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases. Karbe will join the company as president and CEO and will serve as a member […]